MedWatch-redaktionen taler om biotekselskabet Orphazyme, Sanofis exit fra diabetesmarkedet og Leo Pharmas nye studieresultater, der giver håb om at kunne konkurrere med blockbustermidlet Dupixent.
The podcast MedWatch is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.